NOVEL HETEROCYCLIC HYBRIDS AS PROMISING SCAFFOLD FOR THE MANAGEMENT OF ALZHEIMER’S DISEASE

A large majority of instances of dementia, which is a chronic neurological disease, are directly associated with Alzheimer's Disease (AD). AD affects cognitive abilities over time and is caused by a variety of mechanisms, but still the cholinergic hypothesis is the most workable approach. This study aims to compile the most recent and interesting scaffolds/scaffold/pharmacophoric combinations to cure AD. In our search for new therapeutic leads for the treatment of AD, some nitrogen and oxygen-containing heterocyclic, including alkaloids, have been highlighted as interesting prospects. The Cholinergic Hypothesis is still the most effective and obvious treatment option for this debilitating and progressive condition and should be used for further study. The outcomes strongly suggest that the hybridization approach is also a successful strategy for identifying novel scaffolds with desirable bioactivities. This article evaluates promising therapeutic compounds and molecules that have recently been introduced as multi-target-directed agents, such as quinoline, quinoxalines, chalcones, coumarins, chromenes, piperazine, carbazoles, tacrine hybrids, donepezil hybrids, rivastigmine hybrids, galantamine hybrids etc. This includes study of workable scaffolds/scaffold/pharmacophoric combinations that may be used as future anti-Alzheimer drugs. We discuss future work that would improve our understanding of this escalating disease.